Download our whitepaper,
"Navigating the Complex Landscape of Obesity Clinical Trials"
What's Inside:
- Key FDA-Approved Pivotal Endpoints for Obesity Clinical Trials.
- Optimizing Recruitment with Adaptive Trial Designs for Obesity.
- Comprehensive Analysis of FDA-Approved Obesity Drugs.
- How Diagnostic Criteria for Obesity Have Evolved and Impact Research.
- Overcoming Common Pitfalls in Obesity Clinical Trials.
- And additional insights to drive your trial's success.
Access your complimentary whitepaper today:
Obesity
Obesity is a serious and potentially life-threatening condition that can impact nearly every aspect of health. It is often associated with complications such as type 2 diabetes, cardiovascular disease, joint problems, and certain types of cancer. If left unmanaged, obesity can lead to significant health issues, reducing quality of life and increasing the risk of premature death.
Advances in the molecular understanding of obesity have opened the door to more targeted therapies. These treatments go beyond traditional weight management approaches, focusing on the biological pathways that drive excessive weight gain. By addressing these underlying mechanisms, targeted therapies aim to improve long-term health outcomes and enhance quality of life.
iNGENū’s team of researchers and clinicians is dedicated to advancing obesity research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by Obesity.
3x
rates of obesity have increased in the USA since 1970
42%
of adults in the USA are obese
25%
of people with obesity may have an undiagnosed metabolic disease
Our clinical team has over
120
years of combined clinical trial experience